683 ESTIMATING THE OVERALL SURVIVAL BENEFIT OF SIPULEUCEL-T IN THE IMPACT TRIAL ACCOUNTING FOR CROSSOVER TREATMENT IN CONTROL SUBJECTS WITH AUTOLOGOUS IMMUNOTHERAPY GENERATED FROM CYROPRESERVED CELLS
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
683 ESTIMATING THE OVERALL SURVIVAL BENEFIT OF SIPULEUCEL-T IN THE IMPACT TRIAL ACCOUNTING FOR CROSSOVER TREATMENT IN CONTROL SUBJECTS WITH AUTOLOGOUS IMMUNOTHERAPY GENERATED FROM CYROPRESERVED CELLS